ATE397084T1 - Lentivirale verpackungskonstrukte - Google Patents

Lentivirale verpackungskonstrukte

Info

Publication number
ATE397084T1
ATE397084T1 AT02704755T AT02704755T ATE397084T1 AT E397084 T1 ATE397084 T1 AT E397084T1 AT 02704755 T AT02704755 T AT 02704755T AT 02704755 T AT02704755 T AT 02704755T AT E397084 T1 ATE397084 T1 AT E397084T1
Authority
AT
Austria
Prior art keywords
cell lines
lentiviral packaging
packaging constructs
lentiviral
present
Prior art date
Application number
AT02704755T
Other languages
English (en)
Inventor
Tianci Luo
Ivan Plavec
Michael Kaleko
Janet Douglas
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE397084T1 publication Critical patent/ATE397084T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Packging For Living Organisms, Food Or Medicinal Products That Are Sensitive To Environmental Conditiond (AREA)
  • Packages (AREA)
AT02704755T 2001-03-13 2002-03-13 Lentivirale verpackungskonstrukte ATE397084T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27527501P 2001-03-13 2001-03-13

Publications (1)

Publication Number Publication Date
ATE397084T1 true ATE397084T1 (de) 2008-06-15

Family

ID=23051582

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02704755T ATE397084T1 (de) 2001-03-13 2002-03-13 Lentivirale verpackungskonstrukte

Country Status (10)

Country Link
US (4) US7070993B2 (de)
EP (2) EP1373536B9 (de)
JP (1) JP4413495B2 (de)
AT (1) ATE397084T1 (de)
CA (1) CA2439067C (de)
DE (1) DE60226852D1 (de)
ES (1) ES2307726T3 (de)
IL (2) IL157335A0 (de)
NZ (1) NZ527937A (de)
WO (1) WO2002072851A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864085B2 (en) * 1999-12-14 2005-03-08 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
DK1395669T3 (da) * 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
IL157335A0 (en) 2001-03-13 2004-02-19 Novartis Ag Lentiviral packaging constructs
JP2005533485A (ja) * 2002-02-04 2005-11-10 ノバルティス アクチエンゲゼルシャフト 組換えウシ免疫不全ウイルスに基づく遺伝子導入システム
KR101269656B1 (ko) 2003-10-24 2013-05-30 셀렉시스 에스. 에이. Ｍａｒ 서열의 복합 트랜스펙션 방법에 의한 포유동물 세포에서의 고효율 유전자 전달 및 발현
US7135339B2 (en) * 2003-11-20 2006-11-14 University Of Iowa Research Foundation Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
WO2007109131A2 (en) * 2006-03-17 2007-09-27 Massachusetts Institute Of Technology Lentiviral vectors that provide improved expression and reduced variegation after transgenesis
WO2010127166A2 (en) 2009-04-30 2010-11-04 The Regents Of The University Of California Combination anti-hiv vectors, targeting vectors, and methods of use
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
GB201202516D0 (en) 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
US20140011980A1 (en) * 2012-07-03 2014-01-09 Allergan, Inc. Methods for sterilizing compositions and resulting compositions
WO2014026053A1 (en) 2012-08-09 2014-02-13 The Regents Of The University Of California Cd25 pre-selective combination anti-hiv vectors, targeting vectors, and methods of use
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
WO2016160618A2 (en) 2015-03-27 2016-10-06 University Of Southern California Car t-cell therapy directed to lhr for the treatment of solid tumors
GB201509040D0 (en) * 2015-05-27 2015-07-08 Oxford Genetics Ltd Cell lines
WO2016197064A1 (en) 2015-06-04 2016-12-08 Epstein Alan L Lym-1 and lym-2 targeted car cell immunotherapy
EP3569244A1 (de) 2015-09-23 2019-11-20 CytoImmune Therapeutics, LLC Flt3-gerichtete car-zellen zur immuntherapie
WO2018185564A2 (en) 2017-04-07 2018-10-11 Uti Limited Partnership Assay to measure the potency of receptor-ligand interactions in nanomedicines
WO2019168923A1 (en) 2018-03-01 2019-09-06 University Of Kansas Techniques for generating cell-based therapeutics using recombinant t cell receptor genes
EP3781182A4 (de) 2018-04-18 2021-11-17 Summa Health Zusammensetzungen und verfahren zur behandlung von ischämie und kardiomyopathie
MX2021002316A (es) 2018-08-31 2021-07-15 Invectys SA Receptores de antígeno quimérico frente a múltiples isoformas de hla-g.
US11912986B2 (en) 2019-09-23 2024-02-27 The Regents Of The University Of California Methods for screening genetic perturbations
AU2021256053A1 (en) 2020-04-17 2022-11-10 City Of Hope FLT3-targeted chimeric antigen receptor modified cells for treatment of FLT3-positive malignancies
EP4277933A4 (de) 2021-01-14 2024-12-11 Senti Biosciences, Inc. Sekretierbare nutzlastregulierung
GB202102832D0 (en) * 2021-02-26 2021-04-14 Ip2Ipo Innovations Ltd Retroviral vectors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5380830A (en) 1989-09-18 1995-01-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Molecular clones of bovine immunodeficiency-like virus
DE69131908T3 (de) 1991-02-19 2008-04-03 Oxford Biomedica (Uk) Ltd. Viruspartikel mit veraendertem wirtspektrum
DE69333471T2 (de) 1992-11-09 2005-02-24 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Erzielbare vektorenpartikel
US5498537A (en) * 1994-03-09 1996-03-12 Cellco, Inc. Serum-free production of packaged viral vector
US5888774A (en) 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
IL127215A0 (en) 1996-06-06 1999-09-22 Novartis Ag Vectors comprising sar elements
EP0991771A2 (de) * 1997-03-06 2000-04-12 Klaus Überla Vektoren, die auf lentiviren basieren und vektorsysteme
US6207455B1 (en) * 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
IL132463A0 (en) 1997-05-13 2001-03-19 Univ North Carolina Lentivirus - based gene transfer vectors
US6004798A (en) 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999036511A2 (en) * 1998-01-16 1999-07-22 Chiron Corporation Feline immunodeficiency virus gene therapy vectors
US6958226B1 (en) 1998-09-11 2005-10-25 The Children's Medical Center Corp. Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
US7329728B1 (en) 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
NZ519034A (en) 1999-12-14 2005-02-25 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
US6864085B2 (en) 1999-12-14 2005-03-08 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
AU2001249170A1 (en) 2000-03-13 2001-09-24 Aptagen Method for modifying a nucleic acid
IL153833A0 (en) 2000-07-18 2003-07-31 Novartis Ag Regulation of gene expression using single-chain, monomeric, ligand dependent polypeptide switches
IL157335A0 (en) * 2001-03-13 2004-02-19 Novartis Ag Lentiviral packaging constructs
JP2005533485A (ja) * 2002-02-04 2005-11-10 ノバルティス アクチエンゲゼルシャフト 組換えウシ免疫不全ウイルスに基づく遺伝子導入システム

Also Published As

Publication number Publication date
EP1967590A3 (de) 2008-09-17
US7442551B2 (en) 2008-10-28
US20070010017A1 (en) 2007-01-11
JP2004523242A (ja) 2004-08-05
DE60226852D1 (de) 2008-07-10
EP1967590A2 (de) 2008-09-10
EP1373536B9 (de) 2009-09-02
AU2002238584B2 (en) 2006-02-23
JP4413495B2 (ja) 2010-02-10
NZ527937A (en) 2005-03-24
ES2307726T3 (es) 2008-12-01
WO2002072851A3 (en) 2003-10-30
EP1373536B1 (de) 2008-05-28
IL185142A0 (en) 2009-02-11
US7700342B2 (en) 2010-04-20
US7070993B2 (en) 2006-07-04
US20080021207A1 (en) 2008-01-24
EP1373536A2 (de) 2004-01-02
CA2439067A1 (en) 2002-09-19
US8183356B2 (en) 2012-05-22
CA2439067C (en) 2011-02-15
US20080268522A1 (en) 2008-10-30
US20030054548A1 (en) 2003-03-20
IL157335A0 (en) 2004-02-19
WO2002072851A2 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
IL185142A0 (en) Lentiviral packaging constructs
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
IL143670A0 (en) Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
SG150550A1 (en) Pharmaceutical preparation containing an antibody for the egf receptor
MY142777A (en) Substituted indole-o-glucosides
BRPI0412402A (pt) polipeptìdeos de amilase termoestáveis, ácidos nucléicos codificando esses polipeptìdeos e seus usos
UA87991C2 (en) Substituted indole-o-glucosides
CY1105772T1 (el) Συνθεσεις και μεθοδοι για βελτιωμενη κυτταρικη καλλιεργεια
DK1450847T3 (da) Apo2-ligand/TRAIL-formuleringer og anvendelser deraf
WO2004046365A3 (en) Interferon-alpha polypeptides and conjugates
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
CY1110225T1 (el) Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
ZA200603731B (en) Plasmid system for multiple expression
AU3281902A (en) Methods for the production of multimeric proteins, and related compositions
AU144678S (en) Bottle
ATE411086T1 (de) Verwendung von granulaten in kosmetischen zusammensetzungen auf basis von pyrogenisch hergestelltem siliziumdioxid
NO992916L (no) Fosfodiesterase 8A
ATE309356T1 (de) Konstruierte fluoreszenzproteine mit langen wellenlängen
HK1054737A1 (zh) 五倍子酸衍生物及其探測內源性凝血的用途
ATE557034T1 (de) Identifikation von epitopen und erniedrigung der allergenität von nahrungsmittelproteinen
TW200504218A (en) Methods for preventing gluconoylation of proteins
WO2003004610A3 (en) Hsst and angiogenesis
ATE466076T1 (de) Gewebe transglutaminase

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1373536

Country of ref document: EP